These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
626 related articles for article (PubMed ID: 23715905)
1. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia. Arbizu J; Prieto E; Martínez-Lage P; Martí-Climent JM; García-Granero M; Lamet I; Pastor P; Riverol M; Gómez-Isla MT; Peñuelas I; Richter JA; Weiner MW; Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1394-405. PubMed ID: 23715905 [TBL] [Abstract][Full Text] [Related]
2. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data. Sörensen A; Blazhenets G; Rücker G; Schiller F; Meyer PT; Frings L; Neuroimage Clin; 2019; 21():101637. PubMed ID: 30553760 [TBL] [Abstract][Full Text] [Related]
3. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Smailagic N; Vacante M; Hyde C; Martin S; Ukoumunne O; Sachpekidis C Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010632. PubMed ID: 25629415 [TBL] [Abstract][Full Text] [Related]
4. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion. Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523 [TBL] [Abstract][Full Text] [Related]
5. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D; Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532 [TBL] [Abstract][Full Text] [Related]
6. The use of individual-based FDG-PET volume of interest in predicting conversion from mild cognitive impairment to dementia. Huang SH; Hsiao WC; Chang HI; Ma MC; Hsu SW; Lee CC; Chen HJ; Lin CH; Huang CW; Chang CC BMC Med Imaging; 2024 Mar; 24(1):75. PubMed ID: 38549082 [TBL] [Abstract][Full Text] [Related]
7. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism. Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A; J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655 [TBL] [Abstract][Full Text] [Related]
8. Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnestic MCI. Tripathi M; Tripathi M; Parida GK; Kumar R; Dwivedi S; Nehra A; Bal C Neurol India; 2019; 67(5):1310-1317. PubMed ID: 31744965 [TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage. Morbelli S; Bauckneht M; Arnaldi D; Picco A; Pardini M; Brugnolo A; Buschiazzo A; Pagani M; Girtler N; Nieri A; Chincarini A; De Carli F; Sambuceti G; Nobili F Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2073-2083. PubMed ID: 28785843 [TBL] [Abstract][Full Text] [Related]
11. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis. Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568 [TBL] [Abstract][Full Text] [Related]
12. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment. Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056 [TBL] [Abstract][Full Text] [Related]
13. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression. Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D; PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116 [TBL] [Abstract][Full Text] [Related]
14. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD). Bauckneht M; Chincarini A; Piva R; Arnaldi D; Girtler N; Massa F; Pardini M; Grazzini M; Efeturk H; Pagani M; Sambuceti G; Nobili F; Morbelli S Alzheimers Res Ther; 2018 Apr; 10(1):35. PubMed ID: 29615111 [TBL] [Abstract][Full Text] [Related]
15. Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment. Groot C; Smith R; Collij LE; Mastenbroek SE; Stomrud E; Binette AP; Leuzy A; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Cho H; Lyoo CH; Frisoni GB; Peretti DE; Garibotto V; La Joie R; Soleimani-Meigooni DN; Rabinovici G; Ossenkoppele R; Hansson O JAMA Neurol; 2024 Aug; 81(8):845-856. PubMed ID: 38857029 [TBL] [Abstract][Full Text] [Related]
16. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study. Inui Y; Ito K; Kato T; J Alzheimers Dis; 2017; 60(3):877-887. PubMed ID: 28922157 [TBL] [Abstract][Full Text] [Related]
17. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI. Ben Bouallègue F; Mariano-Goulart D; Payoux P; J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345 [TBL] [Abstract][Full Text] [Related]
18. (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Zhang S; Smailagic N; Hyde C; Noel-Storr AH; Takwoingi Y; McShane R; Feng J Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010386. PubMed ID: 25052054 [TBL] [Abstract][Full Text] [Related]
19. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting. Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117 [TBL] [Abstract][Full Text] [Related]
20. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum. Roy K; Pepin LC; Philiossaint M; Lorius N; Becker JA; Locascio JJ; Rentz DM; Sperling RA; Johnson KA; Marshall GA J Alzheimers Dis; 2014; 42(1):291-300. PubMed ID: 24898635 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]